Polarean Imaging PLC New system order (1269J)
April 25 2022 - 2:00AM
UK Regulatory
TIDMPOLX
RNS Number : 1269J
Polarean Imaging PLC
25 April 2022
Polarean Imaging Plc
("Polarean" or the "Company")
New system order
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with an investigational drug--device
combination product using hyperpolarised (129) Xenon gas to enhance
magnetic resonance imaging (MRI) in pulmonary medicine, announces
it has received an additional research unit order for a Xenon
Polariser 9820. The system will be installed in the Center for
Pulmonary Imaging Research at the Cincinnati Children's Medical
Center ("CCHMC"). The Company holds a Small Business Innovation
Research grant with the Cincinnati Children's Center, awarded by
the National Heart, Lung and Blood Institute (NHLBI) in April
2017.
CCHMC is a non-profit academic medical center, which is
distinguished and globally renowned for paediatric teaching and
research, and is one of the Company's longest key clinical
collaborators. A key focus of the collaboration is to lead the
field of paediatric pulmonary imaging through advanced imaging
techniques and multi-nuclear capabilities, including hyperpolarised
(129) Xenon gas.
Jason Woods, Director at the Center for Pulmonary Imaging
Research commented: " We're excited to expand our capabilities with
an additional hyperpolariser, which will facilitate and accelerate
clinical trials in the CCHMC and within the Xe MRI Clinical Trials
Consortium. This model also allows future potential increases in
demand."
Richard Hullihen, CEO of Polarean Imaging said: " We are pleased
to announce the ordering of the latest model of our xenon polariser
from the CCHMC . We are delighted to be able to support their
exceptional programme for advancing non-invasive hyperpolarised
noble gas MR imaging in paediatric research. The CCHMC have made
significant progress in their breakthrough efforts in early
detection, therapy development, evaluation and management and we
believe our partnership can help them improve the outcomes for the
most vulnerable of patients."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, investigational
drug-device combination companies operating in the high-resolution
medical imaging research space.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation. (129) Xe gas is currently
being studied for visualisation of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue membrane,
and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application
("NDA") to the FDA for hyperpolarised (129) Xe used to evaluate
pulmonary function and to visualise the lung using MRI. The Group
received a complete response letter on 6 October 2021.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel investigational
diagnostic approach, offering a non-invasive and radiation-free
functional imaging platform. The annual economic burden of
pulmonary disease in the US is estimated to be over US $150
billion. Cincinnati Children's Medical Center
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBGGDSSBDDGDS
(END) Dow Jones Newswires
April 25, 2022 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024